SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic
CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria (HCU).
Gout is a complex form of inflammatory arthritis that occurs when excess uric acid in the body forms crystals in the joints. Patients experience symptoms such as intense joint pain, inflammation and redness, and limited range of motion in the affected joints. Current treatment options present limitations in both safety and efficacy, highlighting a need for new approaches. In addition, gout is a recognized risk factor in chronic kidney disease. SYNB2081 is a Synthetic Biotic designed to lower uric acid.
"With our second drug candidate into clinical development, this not only demonstrates the value of combining Ginkgo's platform with our Synthetic Biotic platform, but also highlights the potential to develop Synthetic Biotics across a range of diseases, giving us the potential to provide meaningful new treatment options to patients in need," said Dr. David Hava, Chief Scientific Officer, Synlogic.
SYNB2081 is named after one of the largest and best-preserved Tyrannosaurus rex specimens in the world. Nicknamed "Sue," the specimen is housed at the Field Museum in Chicago and is officially named FMNH PR 2081. Data from "Sue" suggests that dinosaurs like the Tyrannosaurus rex suffered from gout much in the same way as other reptiles and birds do.
"The advancement of SYNB2081 and SYNB1353 are clear indicators of the transformative platform Synlogic has created to develop new Synthetic Biotics through synthetic biology," said Patrick Boyle, Head of Codebase for Ginkgo. "We're honored to work with the Synlogic team in this pioneering next step to potentially help patients living with gout. As we've seen the Synlogic pipeline develop over the past year, we're eager to continue supporting Synlogic in generating additional therapeutic candidates."
About Synlogic
Synlogicis a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic's pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic's reproducible, target-specific drug design.Synlogicuses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. In addition to its clinical programs,Synlogichas a research collaboration with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease. Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. For additional information visitwww.synlogictx.com.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit http://www.ginkgobioworks.com.
Forward-Looking Statements of Synlogic
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward," "estimate," "expect," "intend," on track," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics, including SYNB2081; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, and (ix) our ability to close and realize the expected benefits of pending merger and acquisition transactions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
SYNLOGIC MEDIA CONTACT:Bill Berry Berry & Company Public Relations 212-253-8881; [emailprotected]
SYNLOGIC INVESTOR CONTACT:Andrew Funderburk Kendall Investor Relations 617-914-0008; [emailprotected]
GINKGO BIOWORKS INVESTOR CONTACT:[emailprotected]
GINKGO BIOWORKS MEDIA CONTACT:[emailprotected]
SOURCE Ginkgo Bioworks
Read the rest here:
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire
- Genetic Engineering (excerpt) - Video [Last Updated On: January 9th, 2012] [Originally Added On: January 9th, 2012]
- Promising early results with therapeutic cancer vaccines [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- Genetic Risk and Stressful Early Infancy Join to Increase Risk for Schizophrenia [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- Innovative cell printing technologies hold promise for tissue engineering R&D [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- SAGE® Labs Creates The First Tissue-Specific Gene Deletion In Rats [Last Updated On: April 21st, 2012] [Originally Added On: April 21st, 2012]
- Devangshu Datta: Towards an HIV cure [Last Updated On: May 5th, 2012] [Originally Added On: May 5th, 2012]
- Now *This* Is a Cell Phone: Using Radio Waves to Control Specific Genes in Mice | 80beats [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- Genetic packing: Successful stem cell differentiation requires DNA compaction, study finds [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- Premier issue of BioResearch Open Access launched by Mary Ann Liebert Inc. publishers [Last Updated On: May 17th, 2012] [Originally Added On: May 17th, 2012]
- GEN reports on growth of tissue engineering revenues [Last Updated On: July 11th, 2012] [Originally Added On: July 11th, 2012]
- New therapeutic target for prostate cancer identified [Last Updated On: July 18th, 2012] [Originally Added On: July 18th, 2012]
- Novel pig model may be useful for human cancer studies [Last Updated On: July 24th, 2012] [Originally Added On: July 24th, 2012]
- New gene therapy strategy boosts levels of deficient protein in Friedreich's ataxia [Last Updated On: July 25th, 2012] [Originally Added On: July 25th, 2012]
- Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma? [Last Updated On: July 26th, 2012] [Originally Added On: July 26th, 2012]
- New marker for identifying precursors to insulin-producing cells in pancreas [Last Updated On: August 22nd, 2012] [Originally Added On: August 22nd, 2012]
- 3D Biomatrix’s Perfecta3D® Hanging Drop Plates Featured in Prominent Life Science Journals [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- Progress in Cell-SELEX compound screening technology reviewed in BioResearch Open Access [Last Updated On: October 18th, 2012] [Originally Added On: October 18th, 2012]
- Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease? [Last Updated On: November 14th, 2012] [Originally Added On: November 14th, 2012]
- Is the detection of early markers of Epstein Barr virus of diagnostic value? [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Genetic Engineering Of Mesenchymal Stem Cells - Video [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Ramble: Simelweis Taboo - Video [Last Updated On: December 12th, 2012] [Originally Added On: December 12th, 2012]
- The Super Protein That Can Cut DNA and Revolutionize Genetic Engineering [Last Updated On: March 22nd, 2013] [Originally Added On: March 22nd, 2013]
- Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents [Last Updated On: June 5th, 2013] [Originally Added On: June 5th, 2013]
- World Stem Cell Summit to be presented by Genetics Policy Institute, Mary Ann Liebert, Inc., and Genetic Engineering ... [Last Updated On: June 11th, 2013] [Originally Added On: June 11th, 2013]
- Genetic engineering - Wikipedia, the free encyclopedia [Last Updated On: November 1st, 2013] [Originally Added On: November 1st, 2013]
- Genetic Engineering: What is Genetic Engineering? [Last Updated On: November 1st, 2013] [Originally Added On: November 1st, 2013]
- Critical factor (BRG1) identified for maintaining stem cell pluripotency [Last Updated On: February 7th, 2014] [Originally Added On: February 7th, 2014]
- Genome Surgery [Last Updated On: February 11th, 2014] [Originally Added On: February 11th, 2014]
- Engineering The Human Genome One Letter At A Time [Last Updated On: February 11th, 2014] [Originally Added On: February 11th, 2014]
- CRISPR is the technology that could allow researchers to perform microsurgery on genes [Last Updated On: February 15th, 2014] [Originally Added On: February 15th, 2014]
- Joseph Glorioso, Ph.D., receives Pioneer Award [Last Updated On: February 19th, 2014] [Originally Added On: February 19th, 2014]
- Commentary: field of tissue engineering is progressing at remarkable pace [Last Updated On: March 5th, 2014] [Originally Added On: March 5th, 2014]
- Pioneer Award recipients Marina Cavazzana and Adrian Thrasher recognized for advancing gene therapy to the clinic for ... [Last Updated On: March 24th, 2014] [Originally Added On: March 24th, 2014]
- New method yields potent, renewable human stem cells with promising therapeutic properties [Last Updated On: March 25th, 2014] [Originally Added On: March 25th, 2014]
- First evidence that very small embryonic-like stem cells [Last Updated On: April 2nd, 2014] [Originally Added On: April 2nd, 2014]
- Scarless wound healing -- applying lessons learned from fetal stem cells [Last Updated On: April 11th, 2014] [Originally Added On: April 11th, 2014]
- Novel marker discovered for stem cells derived from human umbilical cord blood [Last Updated On: April 18th, 2014] [Originally Added On: April 18th, 2014]
- GENs Top 10 Session Picks for the 2014 BIO International Convention [Last Updated On: May 2nd, 2014] [Originally Added On: May 2nd, 2014]
- A Vaccine for Heart Disease Could Mean No Pills, Lettuce or a Gym [Last Updated On: June 14th, 2014] [Originally Added On: June 14th, 2014]
- Gene editing tool can write HIV out of the picture [Last Updated On: June 22nd, 2014] [Originally Added On: June 22nd, 2014]
- Inner ear stem cells hold promise for restoring hearing [Last Updated On: June 24th, 2014] [Originally Added On: June 24th, 2014]
- New method to grow zebrafish embryonic stem cells can regenerate whole fish [Last Updated On: June 30th, 2014] [Originally Added On: June 30th, 2014]
- Novel methods may help stem cells survive transplantation into damaged tissues [Last Updated On: July 22nd, 2014] [Originally Added On: July 22nd, 2014]
- New method for reducing tumorigenicity in induced pluripotent stem-cell based therapies [Last Updated On: July 24th, 2014] [Originally Added On: July 24th, 2014]
- Malcolm K. Brenner receives Pioneer Award for advances in gene-modified T cells targeting cancer [Last Updated On: July 26th, 2014] [Originally Added On: July 26th, 2014]
- Conclusive evidence on role of circulating mesenchymal stem cells in organ injury [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- New genomic editing methods produce better disease models from patient-derived iPSCs [Last Updated On: September 8th, 2014] [Originally Added On: September 8th, 2014]
- Tory Williams combats controversy surrounding stem cell therapy with new book [Last Updated On: September 11th, 2014] [Originally Added On: September 11th, 2014]
- NYIT Expert Predicts Growth in Demand for 3D Kidneys, Livers and Hearts [Last Updated On: December 9th, 2014] [Originally Added On: December 9th, 2014]
- The 'Berlin patient,' first and only person cured of HIV, speaks out [Last Updated On: January 6th, 2015] [Originally Added On: January 6th, 2015]
- Integrins are essential in stem cell binding to defective cartilage for joint regeneration [Last Updated On: January 27th, 2015] [Originally Added On: January 27th, 2015]
- Scientists urge caution in using new CRISPR technology to treat human genetic disease [Last Updated On: March 20th, 2015] [Originally Added On: March 20th, 2015]
- Scientists call for caution in using DNA-editing technology [Last Updated On: March 23rd, 2015] [Originally Added On: March 23rd, 2015]
- 'Ban DNA Editing Of Sperm And Eggs' [Last Updated On: March 23rd, 2015] [Originally Added On: March 23rd, 2015]
- Mount Sinai Researchers Discover Genetic Origins of Myelodysplastic Syndrome Using Stem Cells [Last Updated On: March 26th, 2015] [Originally Added On: March 26th, 2015]
- Researchers discover genetic origins of myelodysplastic syndrome using stem cells [Last Updated On: March 26th, 2015] [Originally Added On: March 26th, 2015]
- Pulling the strings of our genetic puppetmasters [Last Updated On: April 6th, 2015] [Originally Added On: April 6th, 2015]
- Going deep on life extension investments and human genetic engineering (Morning Read) [Last Updated On: April 6th, 2015] [Originally Added On: April 6th, 2015]
- Genetic engineering: a guide for kids by Tiki the Penguin [Last Updated On: July 8th, 2015] [Originally Added On: July 8th, 2015]
- genetic engineering | Britannica.com [Last Updated On: July 20th, 2015] [Originally Added On: July 20th, 2015]
- Interactives . DNA . Genetic Engineering [Last Updated On: August 3rd, 2015] [Originally Added On: August 3rd, 2015]
- Genetic engineering - Memory Alpha, the Star Trek Wiki [Last Updated On: September 10th, 2015] [Originally Added On: September 10th, 2015]
- Genetic Engineering Careers in India : How to become a ... [Last Updated On: September 10th, 2015] [Originally Added On: September 10th, 2015]
- Genetic Engineering (song) - Wikipedia, the free encyclopedia [Last Updated On: August 8th, 2016] [Originally Added On: August 8th, 2016]
- Genetic Engineering - BiologyMad [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- UNL's AgBiosafety for Educators [Last Updated On: September 28th, 2016] [Originally Added On: September 28th, 2016]
- Recent Articles | Genetic Engineering | The Scientist ... [Last Updated On: October 20th, 2016] [Originally Added On: October 20th, 2016]
- Human Genetic Engineering - Popular Issues [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Explore More: Genetic Engineering - iptv.org [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Genetic Engineering and GM Crops - Pocket K | ISAAA.org [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Pros and Cons of Genetic Engineering | HRFnd [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering - The New York Times [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering | MSPCA-Angell [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- What is genetic engineering? - Definition from WhatIs.com [Last Updated On: November 10th, 2016] [Originally Added On: November 10th, 2016]
- Genetic Engineering in Agriculture | Union of Concerned ... [Last Updated On: November 16th, 2016] [Originally Added On: November 16th, 2016]
- Free genetic engineering Essays and Papers - 123helpme [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Gene therapy - Wikipedia [Last Updated On: November 20th, 2016] [Originally Added On: November 20th, 2016]
- Writing the human genome - The Biological SCENE [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- America's First Free-Roaming Genetically Engineered Insects Are ... - Gizmodo [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Stanford's Final Exams Pose Question About the Ethics of Genetic Engineering - Futurism [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]